GUIDANCE ON THERAPEUTIC PRODUCT REGISTRATION IN SINGAPORE NOVEMBER 2016
– GUIDELINE ON THE REGISTRATION OF HUMAN THERAPEUTIC PRODUCTS CONTAINING
MATERIALS OF ANIMAL ORIGIN
HEALTH SCIENCES AUTHORITY – HEALTH PRODUCTS REGULATION GROUP Appendix 9 - Page 6 of 10
tissue, heart/ pericardium, lung, liver, kidney, adrenal, pancreas,
bone marrow, skeletal muscle, tongue, blood vessels, nasal
mucosa, salivary gland, cornea, blood, cerebrospinal fluid, saliva,
milk, urine, faeces.
Category IC (No Detectable Infectivity): semen, placenta fluids,
prostate/ epididymis/ seminal vesicle, foetus, embryo, bone,
tendon, gingival tissues, dental pulp, trachea, thyroid gland,
colostrum, cord blood, sweat, tears, nasal mucus, bile
Specific considerations:
Gelatin may be extracted from the hide and/or bones of cattle.
Gelatin extracted from hide has a lower risk than gelatin extracted
from bones. When bones are used to manufacture gelatin, skulls
and spinal cord should be removed from the collected bones
independent of the age or the country of origin of the cattle. Hide
gelatin offers little opportunity for cross-contamination with
potentially infective tissue (e.g. brain, spinal cord and ganglia).
Thus, it is recommended to collect bovine bones for processing into
gelatin only from BSE-free countries or from countries with a low
prevalence of BSE. Gelatin should be manufactured using the acid,
alkaline or heat/ pressure manufacturing process.
Materials derived from ruminant tallow, such as triglycerides,
glycerol, sorbitan esters and polysorbate, or amino acids of
ruminant origin (even if higher-risk tissues were not completely
eliminated) are considered highly unlikely to remain infectious by
the time the final reagent has been produced, as long as they were
manufactured under the conditions at least as rigorous as those
specified in EMA’s Note for Guidance.
b. In certain situations, there could be cross-contamination of tissues
from different categories of infectivity, e.g. direct contact between